Coadministration has not been studied. Coadministration of ticagrelor with strong inhibitors of CYP3A4 (such as darunavir/cobicistat) is contraindicated, as it may lead to a substantial increase in exposure to ticagrelor and bleeding risk. Use of other antiplatelets not affected by CYP inhibition or induction is recommended. Based on metabolism and clearance, a clinically significant interaction with emtricitabine and tenofovir alafenamide is unlikely.